A Phase I Dose Escalation Study of VS-4718, A Focal Adhesion Kinase Inhibitor, In Subjects With Relapsed or Refractory Acute Myeloid Leukemia or B-Cell Acute Lymphoblastic Leukemia
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs VS 4718 (Primary)
- Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Solid tumours
- Focus Adverse reactions
- Sponsors Verastem
- 19 Oct 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 19 Aug 2014 New trial record
- 14 Aug 2014 Planned End Date changed from 1 Mar 2016 to 1 Nov 2016, according to the ClinicalTrials.gov record.